Initially, physicians should pursue either genome sequencing or exome sequencing coupled with chromosomal microarray. If that is inconclusive, then the guidance recommends screening for treatable ...

Table 3. Comparison of Chromosomal Abnormality Rates Detected by Chromosome microarray analysis among Different Types of Fetal Cardiac Anomalies. Table 4. Associations between cardiac anomaly type and ...

Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ C ...

“Thermo Fisher’s unparalleled commitment to driving innovation in chromosomal microarrays has led to advancement of cytogenetic testing capabilities,” said Kevin Lowitz, vice president and general ...

The assay is based on chromosomal microarray technology, and it is designed for use on the company's SureScan Dx Microarray Scanner system with analysis through its CytoDx software. Most molecular ...

Instead, the clinician should consider more expansive testing such as panel or exome sequencing if not already performed. CMA indicates chromosomal microarray analysis; and SVAS, supravalvar aortic ...

Stone also noted that insurance companies usually cover chromosomal microarray but don't often cover whole-genome sequencing.

Bionano Genomics, Inc. announced a publication covering the largest independent prospective prenatal study comparing optical genome mapping to a combined workflow of chromosomal microarray analysis ...